FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
18 letters match. Newest first.
-
DrugsCDL Services, Inc. DBA Technichem
FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.
High risk -
DrugsColumbia Cosmetics Manufacturing Inc.
Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.
High risk -
DrugsKabana Skin Care LLC
Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.
High risk -
DrugsDyno Manufacturing, Inc.
Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.
High risk -
DrugsRite-Kem Incorporated
FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.
High risk -
DrugsHangzhou Huiji Biotechnology Co., Ltd.
FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.
High risk -
DrugsDiora Kimya Sanayi ve Ticaret Limited Sirketi
FDA cited Diora Kimya for drug manufacturing quality failures and for an unlisted antibacterial soap.
High risk -
DrugsAnuMed International, LLC
FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.
High risk -
DrugsArt of Beauty Company, Inc.
FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.
High risk -
DrugsreBom Co., Ltd.
reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.
High risk -
DrugsLandy International
FDA found Landy International’s OTC hand sanitizers adulterated after a 2023 inspection revealed missing testing, unsafe water, and data integrity failures.
High risk -
DrugsC&T Dream Co., Ltd.
C&T Dream failed CGMP (current good manufacturing practice) for its over-the-counter Dry Skin Healing Ointment, including identity testing and process validation.
High risk -
DrugsFirstCham Co., Ltd.
FDA warns FirstCham over current good manufacturing practice violations and misbranding of Soo'Ae hand sanitizing wipes.
High risk -
DrugsHigley Industries, Inc.
FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.
High risk -
DrugsPrime Lab LLC
Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.
High risk -
DrugsLex Inc.
FDA warns Lex Inc. of Medley, Florida, that its over-the-counter drugs are adulterated because manufacturing rules were not met, including missing toxic-ingredient testing.
High risk -
DrugsDenison Pharmaceuticals, LLC
Denison Pharmaceuticals was cited for manufacturing quality failures, contamination risks, and unapproved infant/homeopathic drugs.
High risk -
DrugsMedgel Private Limited
FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.
High risk